文献速递衰弱、肌少症与跌倒老年综合评估

Bimagrumab治疗肌少症的II期随机对照概念验证研究

Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study.
PubMed 文献 · J Am Geriatr Soc · 2017-06-27

这项24周、双盲、安慰剂对照的II期研究纳入40名≥65岁、步速0.4–1.0 m/s且四肢骨骼肌指数符合阈值的社区居住肌少症老人,比较静脉bimagrumab 30 mg/kg与安慰剂。bimagrumab组大腿肌肉体积自第2周起持续增加并高于基线,基线步速较慢者第16周步速和6分钟步行距离改善更显著;不良事件多为轻度和可缓解。

要点

  • bimagrumab 30 mg/kg静脉给药可使肌少症老人大腿肌肉体积自第2周起持续增加至研究结束。
  • 基线步速较慢者第16周步速平均改善0.15 m/s、6分钟步行距离平均改善82 m,优于安慰剂。
  • 不良事件包括肌肉相关症状、痤疮和腹泻,多为轻度且研究结束时缓解。

核心结论

  • bimagrumab治疗16周可增加肌少症老人的肌肉量和力量,并改善步速较慢者的活动能力。

研究设计与样本

  • 24周随机、双盲、安慰剂对照、平行组概念验证研究,在美国5个中心开展。
  • 共纳入40名≥65岁社区居住老人,bimagrumab组19例、安慰剂组21例,32例(80%)完成研究。

主要发现

  • bimagrumab组大腿肌肉体积较基线增加:第2周5.15±2.19% vs 安慰剂-0.34±2.59%(P<.001),第4周6.12±2.56% vs 0.16±3.42%(P<.001),第8周8.01±3.70% vs 0.35±3.32%(P<.001),第16周7.72±5.31% vs 0.42±5.14%(P<.001),第24周4.80±5.81% vs -1.01±4.43%(P=.002)。
  • 基线步速较慢者接受bimagrumab后第16周步速平均改善0.15 m/s(P=.009)、6分钟步行距离平均改善82 m(P=.022),优于安慰剂。
  • bimagrumab组不良事件包括肌肉相关症状、痤疮和腹泻,多为轻度,研究结束时缓解。

关键数值与推荐

  • 入组标准:年龄≥65岁,4米步速0.4–1.0 m/s,四肢骨骼肌指数男性≤7.25 kg/m2、女性≤5.67 kg/m2。
  • 干预方案:静脉bimagrumab 30 mg/kg或安慰剂。

临床怎么用

  • 对符合入组标准的肌少症老人,bimagrumab可能作为增加肌肉量和改善活动能力的候选药物,尤其适用于步速较慢者。
  • 用药期间需关注肌肉相关症状、痤疮和腹泻等不良事件,多数为轻度且可缓解。

局限性

  • 本研究为样本量40例的II期概念验证研究,完成率80%,结果需更大规模研究验证。
  • 研究仅在美国5个中心开展,随访24周,长期疗效和安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the effects of bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations. DESIGN: A 24-week, randomized, double-blind, placebo-controlled, parallel-arm, proof-of-concept study. SETTING: Five centers in the United States. PARTICIPANTS: Community-dwelling adults (N = 40) aged 65 and older with gait speed between 0.4 and 1.0 m/s over 4 m and an appendicular skeletal muscle index of 7.25 kg/m2 or less for men and 5.67 kg/m2 or less for women. INTERVENTION: Intravenous bimagrumab 30 mg/kg (n = 19) or placebo (n = 21). MEASUREMENTS: Change from baseline in thigh muscle volume (TMV), subcutaneous and intermuscular fat, appendicular and total lean body mass, grip strength, gait speed, and 6-minute walk distance (6MWD). RESULTS: Thirty-two (80%) participants completed the study. TMV increased by Week 2, was sustained throughout the treatment period, and remained above baseline at the end of study in bimagrumab-treated participants, whereas there was no change with placebo treatment (Week 2: 5.15 ± 2.19% vs -0.34 ± 2.59%, P < .001; Week 4: 6.12 ± 2.56% vs 0.16 ± 3.42%, P < .001; Week 8: 8.01 ± 3.70% vs 0.35 ± 3.32%, P < .001; Week 16: 7.72 ± 5.31% vs 0.42 ± 5.14%, P < .001; Week 24: 4.80 ± 5.81% vs -1.01 ± 4.43%, P = .002). Participants with slower walking speed at baseline receiving bimagrumab had clinically meaningful and statistically significantly greater improvements in gait speed (mean 0.15 m/s, P = .009) and 6MWD (mean 82 m, P = .022) than those receiving placebo at Week 16. Adverse events in the bimagrumab group included muscle-related symptoms, acne, and diarrhea, most of which were mild in severity and resolved by the end of study. CONCLUSION: Treatment with bimagrumab over 16 weeks increased muscle mass and strength in older adults with sarcopenia and improved mobility in those with slow walking speed.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Rooks D, Praestgaard J, Hariry S, et al. Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study. J Am Geriatr Soc. 2017. PMID: 28653345. doi:10.1111/jgs.14927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。